Titan Medical to Present at the Benzinga Global Small Cap Conference
December 03 2020 - 7:30AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”) (TSX:
TMD) (Nasdaq: TMDI), a medical device company focused on the
design and development of surgical technologies for robotic single
access surgery, announced today that David McNally, President, CEO
and Chairman of Titan Medical, will present an overview of the
Company and its Enos™ single access surgical system to a live
virtual audience at the Benzinga Global Small Cap Conference on
Wednesday, December 9, 2020 at 1:30 p.m. ET. To view Mr. McNally’s
presentation, please register in advance at:
https://www.benzinga.com/events/small-cap/.
Benzinga is a financial media company providing syndicated
content to 70 partner websites, including Yahoo! Finance MSN,
CNNMoney, Fox Business and MarketWatch. Dedicated to making
information easier to consume, Benzinga is hosting its inaugural
Global Small Cap Conference to help bridge the gap between publicly
traded companies, investors, and traders, enabling small-cap
companies to network and communicate with a broad and diverse
investor base.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in
Toronto, is focused on developing robotic assisted technologies for
application in single access surgery. The Enos system, by Titan
Medical, is being developed to become the new standard of care in
robotic single access surgery, with dual 3D and 2D high-definition
vision systems, multi-articulating instruments, and an ergonomic
surgeon workstation. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Certain of Titan’s robotic assisted surgical technologies and
related intellectual property have been licensed to Medtronic plc,
while retaining world-wide rights to commercialize the technologies
for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including references to: the Company’s focus on the
design and development of surgical technologies for robotic single
access surgery; the Company being focused on developing robotic
assisted technologies for application in single access surgery; the
Enos system being developed to become the new standard of care in
robotic single access surgery with dual 3D and 2D high-definition
vision systems, multi-articulating instruments, and an ergonomic
surgeon workstation; the Company’s intention to initially pursue
gynecologic surgical indications. These statements reflect
management’s current beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements, including,
without limitation, those listed in the “Risk Factors” section of
the Company’s Annual Report on Form 20F dated March 30, 2020 (which
may be viewed at www.sedar.com and at www.sec.gov). Should one or
more of these risks or uncertainties materialize, or should
assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005150/en/
Monique L. Delorme Chief Financial Officer +1-416-548-7522
investors@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Sep 2023 to Sep 2024